Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide
| Autor: | Guillermo Alberto Keller, Claudio Gonzalez, Valeria Beruto, Guillermo Di Girolamo, Silvina Santoro |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Blood Glucose
endocrine system medicine.medical_specialty Body weight Glucagon-Like Peptide 1 Insulin-Secreting Cells Internal medicine medicine Animals Humans Hypoglycemic Agents Insulin Pharmacology (medical) Insulin secretion Cell Proliferation Randomized Controlled Trials as Topic Pharmacology Gastric emptying Venoms Liraglutide business.industry Body Weight digestive oral and skin physiology Glucagon secretion Type 2 Diabetes Mellitus Drugs Investigational General Medicine Glucagon Endocrinology Postprandial Diabetes Mellitus Type 2 Gastric Emptying Exenatide Peptides business medicine.drug |
| Zdroj: | Expert Opinion on Investigational Drugs. 15:887-895 |
| ISSN: | 1744-7658 1354-3784 |
| Popis: | Although a number of compounds are currently used to treat Type 2 diabetes mellitus, achieving a sustained glycaemic control over time is often not possible using oral antidiabetics. Endogenous incretins exhibit beneficial effects that could be useful for Type 2 diabetes mellitus treatment, such as stimulating insulin secretion during hyperglycaemia, improving beta-cell mass and function, reducing glucagon secretion, delaying gastric emptying, reducing postprandial hyperglycaemia and diminishing body weight; however, their short half-life makes them unsuitable for treatment. Incretin mimetics such as liraglutide and exenatide were developed to overcome this limitation. This review discusses the effects of these compounds and their potential as a new class of antidiabetic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|